Tonix Pharmaceuticals has received US Food Drug and Administration (FDA) approval to initiate a comparative pharmacokinetic and bioavailability study of TNX-102, an oral formulation of cyclobenzaprine for the treatment of fibromyalgia.
TNX-102 is a gelcap containing very low dose cyclobenzaprine, designed for faster and improved absorption relative to conventional cyclobenzaprine products.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
About 30 healthy adult volunteers will be enrolled in the single-dose, open-label, randomised and three-way crossover study, which will compare a TNX-102 candidate gelcap containing 2.4mg of cyclobenzaprine to a 5mg cyclobenzaprine tablet.
Additionally, the study will assess the effect of food on the pharmacokinetic profile of TNX-102 in subjects who are either fasting or fed with a high-fat, high-calorie breakfast.
Tonix chairman and president Seth Lederman said that if the study validates the company’s hypothesis, it would proceed with the first of two pivotal clinical trials.
"Our goal is to develop a bedtime cyclobenzaprine treatment with more predictable beneficial effects and possibly reduced next day drowsiness," Lederman said.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
